Biomarkers
INNOVHEM has developed NOVEL BIOMARKERS that are specifically designed towards the pathophysiology of sickle cell disease. They allow to better understand disease progression and to monitor treatment efficacy.
INNOVHEM’s proprietary biomarkers have already been used to assist pharmaceutical and biotech companies in their clinical R&D programs aimed at introducing new effective treatments of sickle cell disease.
In sickle cell disease, fetal hemoglobin (HbF) is a protective factor. The single cell quantification of HbF is the only measure that directly correlates to the severity of the symptoms in sickle cell disease patients. (Steinberg et al.,2014)
Quantification principle
Based on flow cytometry and a standard curve to transform fluorescence intensity into pg of HbF per cell.
Treatment follow-up
INNHOVHEM’s measure is the only method correlated to VOC
Since hemolysis is the primary cause of the anemia aspect of sickle cell disease, its precise quantification is of high importance to better monitor patients or to assess treatment efficacy. Because of the poor reliability of standard-of-care biomarkers (ASAT, ALAT, LDH) to diagnose hemolysis, we have developed a unique method to measure precise hemolysis biomarkers in the plasma/serum : Hemoglobin (HbO2), Methemoglobin (MetHb), Heme, Hemopexin and total bilirubin.
Quantification principle
An analytic method based on light absorbance in plasma/serum.
Spectral analytical measure of hemolysis biomarkers
Proof of concept
Plasma heme can discriminate the severity of renal damage
Diagnosis of DHTR
Key advantages
AN IMPROVED CHARACTERIZATION OF THE DISEASE FOR PATIENTS AND PHYSICIANS
A VALUABLE ASSESSMENT OF TREATMENT EFFICACY FOR PHYSICIANS AND INDUSTRY